CSL (ASX:CSL) has put kidney and liver disease firmly in focus, committing an upfront US$355 million to partner with Alentis Therapeutics on lixudebart and agreeing to fund upcoming Phase 2 and 3 trials.
CSL's move on lixudebart lands after a sharp shift in sentiment, with the 90-day share price return of 43.75% contrasting with a 1-year total shareholder return that declined 10.72%. This signals short term momentum building against a weaker multi year record.
Scan other kidney and liver focused opportunities moving on fresh catalysts with our hand picked 8 healthcare AI stocks alongside CSL's latest lixudebart partnership news.
CSL now trades only a little below the average analyst target, yet appears to be at a wider intrinsic discount and has just added a US$355 million kidney and liver bet. Where does fair value really land after that kind of reset?
Most Popular Narrative: 14.9% Undervalued
Against CSL's last close at A$178.68, the most followed narrative points to a fair value of A$210.00, implying a noticeable valuation gap that this lixudebart deal plugs into rather than defines.
CSL is one of Australia's highest-quality businesses and has a long history of delivering strong returns. It is a global leader in plasma therapies, vaccines and biotechnology, with products that are difficult to replicate and protected by strict regulation. Healthcare demand tends to remain resilient regardless of economic conditions.
See why 41 investors see CSL as 15% undervalued .
Result: Fair Value of A$210.00 (UNDERVALUED)
Still, CSL faces real pressure if kidney and liver trials disappoint, or if regulatory setbacks slow the broader pipeline and weaken confidence in that 14.9% discount.
Find out about the key risks to this CSL narrative .
Next Steps
Mixed signals on CSL's outlook so far. If you want to move fast and rely on your own judgment, start by weighing the 3 key rewards and 1 important warning sign .
Looking for more ideas beyond CSL?
If CSL has sharpened your focus on quality and risk, you might use this moment to line up a few more thoughtful contenders on your watchlist.
-
Scan for companies with dependable balance sheets and resilient fundamentals through the list of solid balance sheet and fundamentals (12 results) .
-
Hunt for stocks that combine quality with potential pricing gaps using the 6 high quality undervalued stocks .
-
Target resilient income ideas that aim to deliver 5%+ yields by reviewing the 3 dividend fortresses .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CSL.AX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
